Definition of interstitial cystitis still controversial

Interstitial cystitis is not an uncommon condition, yet researchers continue in their struggle to define it and reach consensus on appropriate diagnostic criteria. In part one of this two-part Urology Times interview, Christopher K. Payne, MD, discusses the current controversy over the definition of IC and his approach to diagnosis.

Related Videos

Related Content

Advertisement

May 12th 2025

National Women’s Health Week: Celebrating women shaping the future of urology

Shaya Taghechian, MD Hannah Clarke

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

Related Content

Advertisement

May 12th 2025

National Women’s Health Week: Celebrating women shaping the future of urology

Shaya Taghechian, MD Hannah Clarke

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.